Dunhill Financial’s Dyne Therapeutics DYN Stock Holding History

Dunhill Financial’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$17	–	1929
2025 Q4	$17	Buy	+1	New	+$19	﹤0.01%	1935

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Dunhill Financial's DYN Position: Q1 2026 in Review

Dunhill Financial sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 1 share — an estimated $17 sold.

Dunhill Financial first reported a position in DYN in Q4 2025 and held it in 1 quarter. The position peaked at $17 in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Dunhill Financial reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
Dunhill Financial sold 1 Dyne Therapeutics share in Q1 2026, an estimated $17.
Dunhill Financial first reported a position in Dyne Therapeutics in Q4 2025 and held it in 1 quarter.
Dunhill Financial's Dyne Therapeutics position peaked at $17 in Q4 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.